GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Total Current Liabilities

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Total Current Liabilities : $61.81 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Clarus Therapeutics Holdings Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Clarus Therapeutics Holdings's total current liabilities for the quarter that ended in Jun. 2022 was $61.81

Clarus Therapeutics Holdings Total Current Liabilities Historical Data

The historical data trend for Clarus Therapeutics Holdings's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarus Therapeutics Holdings Total Current Liabilities Chart

Clarus Therapeutics Holdings Annual Data
Trend Dec20 Dec21
Total Current Liabilities
59.81 66.06

Clarus Therapeutics Holdings Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Total Current Liabilities Get a 7-Day Free Trial - 64.38 66.06 65.95 61.81

Clarus Therapeutics Holdings Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Clarus Therapeutics Holdings's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=20.201+42.269
+Other Current Liabilities+Current Deferred Liabilities
=2.005+1.585
=66.06

Clarus Therapeutics Holdings's Total Current Liabilities for the quarter that ended in Jun. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=16.449+40.505
+Other Current Liabilities+Current Deferred Liabilities
=1.873+2.979
=61.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Clarus Therapeutics Holdings Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Clarus Therapeutics Holdings's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Clarus Therapeutics Holdings Inc (OTCPK:CRXTQ) » Definitions » Total Current Liabilities
Comparable Companies
JMAC KYCH OOGI SMAP ADRT BYNO MEPW TUGC GIAC ARIZ JNJ PFE XSWX:ROG LLY ABBV MRK LSE:AZN XSWX:NOVN BMY XPAR:SAN
Traded in Other Exchanges
N/A
Address
555 Skokie Boulevard, Suite 340, Northbrook, IL, USA, 60062
Website
https://www.clarustherapeutics.com
Clarus Therapeutics Holdings Inc is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company is focused on focused on the commercialization of JATENZO (testosterone undecanoate), the first and only oral testosterone replacement, or testosterone replacement therapy, and JATENZO is the sole source of company's revenue.
Executives
Thomas Mcnerney & Partners Lp 10 percent owner 45 S. 7TH ST., SUITE 3060, MINNEAPOLIS MN 55402
Kimberly M Murphy director 101 EAST KENNEDY BLVD., SUITE 2800, TAMPA FL 33602
Elizabeth Cermak director 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Prygocki Mark A Sr director C/O MEDICS, 8125 N. HAYDEN RD, SCOTTSDALE AZ 85258
John Kenneth Amory director C/O CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Robert E. Dudley director, officer: Chief Executive Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Joseph Hernandez director C/O MICROLIN BIO, INC., NEW YORK NY 10022
Richard D Peterson officer: Chief Financial Officer 1110 WEST COMMERCIAL BOULEVARD, FORT LAUDERDALE FL 33309
Frank Jaeger officer: Chief Commercial Officer CLARUS THERAPEUTICS HOLDINGS, INC., 555 SKOKIE BLVD, SUITE 340, NORTHBROOK IL 60662
Steven A. Bourne officer: Chief Administrative Officer 555 SKOKIE BOULEVARD, SUITE 340, NORTHBROOK IL 60062
Ffi Fund Ltd 10 percent owner DMS HOUSE, 20 GENESIS CLOSE, GRAND CAYMAN, GEORGE TOWN E9 KY1-1208
Thomas, Mcnerney & Partners Ii L.p. 10 percent owner 45 SOUTH 7TH STREET, SUITE 3060, Minneapolis MN 55402
Thomas, Mcnerney & Partners Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Nominee Ii, Llc 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402
Tmp Associates Ii Lp 10 percent owner 45 SOUTH SEVENTH STREET, SUITE 3060, MINNEAPOLIS MN 55402

Clarus Therapeutics Holdings (Clarus Therapeutics Holdings) Headlines

From GuruFocus

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at ENDO 2022, the Endocrine Society's Annual Meeting

By GuruFocusNews GuruFocusNews • 07-09-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

By GuruFocusNews GuruFocusNews • 06-28-2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

By GuruFocusNews GuruFocusNews • 06-19-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

By GuruFocusNews GuruFocusNews • 06-08-2022

Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

By GuruFocusNews GuruFocusNews • 06-21-2022

Clarus Therapeutics Reports First Quarter 2022 Financial and Operating Results

By PurpleRose PurpleRose • 07-15-2022

Clarus Therapeutics to Present New Data for JATENZO� (testosterone undecanoate) at the 2022 American Urological Association Annual Meeting

By GuruFocusNews GuruFocusNews • 05-29-2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO� (testosterone undecanoate)

By GuruFocusNews GuruFocusNews • 06-07-2022

Clarus Therapeutics Announces Issuance of Patent Covering JATENZO� (testosterone undecanoate)

By GuruFocusNews GuruFocusNews • 06-17-2022

Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis

By GuruFocusNews GuruFocusNews • 06-09-2022